Anti-Rheumatics Market Growth rates in key countries and regions have converged since 2018 to a range of 8–11% in 2020
Pune, Maharashtra, India, September 10 2020 (Wiredrelease) Allied Analytics –:Global Anti-rheumatics market was valued at $57 billion in 2018, and is expected to reach $71 billion by 2026, registering a CAGR of 2.9% from 2019 to 2026.
Rheumatoid arthritis is an autoimmune disorder, which causes painful and swollen joints in patients. The treatment of this medical condition involves the use of various drugs, known as anti-rheumatics. For instance, different type of drugs involved in the treatment of rheumatoid arthritis include disease modifying anti-rheumatic drugs (DMARD’s), nonsteroidal anti-inflammatory drugs (NSAID’s), corticosteroids, and others. These drugs have different mechanism of action on the medical condition. For instance, DMARDs modify the course of the action and NSAIDs act on the symptoms of the disease such as pain. Furthermore, these drugs are available on prescription and also over-the-counter.
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/6289
The disease modifying anti-rheumatic drugs (DMARDs) segment to maintain its lead position by 2026
Based on drug class, the disease modifying anti-rheumatic drugs (DMARDs) segment held more than one-third of the total market share of the global anti-rheumatics market in 2018, and is expected to maintain its lead position throughout the forecast period. This is due to its action on the medical conditions rather than acting on the symptoms. However, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow at the fastest CAGR of 3.7% from 2019 to 2026. This is attributed to the rise in incidences of rheumatoid arthritis regarding pain in the joints.
The prescription-based drugs segment to maintain its dominance by 2026
Based on type, the prescription-based drugs segment accounted for the highest share in the global anti-rheumatics market in 2018, contributing for more than three-fourths of the total share, and is estimated to maintain its dominance in terms of revenue throughout the forecast period. This is due to increase in the number of specialized hospitals across the world that provide treatment from specialized medical professionals. However, the over-the-counter drugs segment is estimated to register the highest CAGR of 3.3% from 2019 to 2026, owing to surge in awareness related to treatment options and ease in availability.
North America to lead in terms of revenue during the forecast period
Based on region, North America held the highest share in 2018, accounting for nearly one-third of the global anti-rheumatics market, and will lead during the forecast period. This is due to easy availability of anti-rheumatics and increase in geriatric population that are susceptible to nephrological disorders. However, Asia-Pacific is estimated to witness the largest growth rate, with a CAGR of 3.7% from 2019 to 2026. This is attributed to increase in healthcare expenditure and surge in awareness of anti-rheumatics.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6289
Leading market players
Pfizer, Inc.Johnson & JohnsonsBristol-Myers Squibb CompanyF. Hoffmann-La Roche Ltd.Celegene CorporationsMedImmune, LLCTakeda Pharmaceutical Company Ltd.Biogen Inc.Celltrion Inc.Amgen Inc.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.